45 F.4th 479
1st Cir.2022Background
- Azurity markets FIRVANQ, an FDA‑approved oral vancomycin product; Edge is a registered 503B outsourcing facility that markets a competing vancomycin oral solution without FDA pre‑approval.
- Edge's website contained: (a) Compliance Statements (claims of compliance with USP/FDA/GMP/503B), (b) Registration Statements (claims of being FDA‑registered and inspected as a 503B), and (c) a Superiority Statement (“commercially available options are not ideal for use in the hospital setting”).
- Azurity sued under the Lanham Act (false advertising/unfair competition) and Mass. Gen. Laws ch. 93A, alleging those statements were literally false and/or misleading and harmed its sales/goodwill.
- The district court dismissed all claims under Rule 12(b)(6), reasoning FDCA enforcement/exclusive administration precluded the Lanham Act claim and consequently the Chapter 93A claim.
- The First Circuit affirmed in part, vacated in part, and remanded: it rejected several theories but held that one Lanham Act theory (Compliance Statements as literally false under §503B’s "bulk drug substance" requirement) survived dismissal; other theories were dismissed for failure to plead actionable falsity/misleadingness or as nonactionable puffery.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether Compliance/Registration statements implying Edge is not violating §503B's "essentially a copy" provision are actionable as literal falsity | Azurity: statements convey Edge is not violating §503B’s "essentially a copy" bar; FIRVANQ and Edge product are identical/nearly identical per FDA guidance | Edge: such statements are legal interpretations/opinions; absent a clear agency or court ruling, they are non‑actionable under Coastal Abstract/Dial A Car; FDCA preclusion | Dismissed. Court held Azurity relied only on non‑binding FDA guidance (not a clear agency ruling or unambiguous statutory text) and thus failed to plausibly allege literal falsity under the legal‑opinion framework |
| Whether Compliance statements are literally false under §503B’s "bulk drug substance" provision (i.e., use of a bulk substance not on the statutorily required lists) | Azurity: §503B plainly conditions outsourcing facility sales on bulk substances being on an FDA list or shortage list; azurity plausibly alleges vancomycin HCl is not on those lists, so Edge’s compliance claims are false | Edge: adjudication would conflict with FDA enforcement discretion / is precluded by FDCA; also disputes factual sufficiency | Survived dismissal. Court found the statutory text is clear on its face regarding bulk substances and Azurity plausibly alleged the substance is not on the required lists; FDCA preclusion did not bar this Lanham theory |
| Whether Registration statements (truthful registration/inspection claims) are misleading re: compliance with §503B (bulk substance) | Azurity: even if literally true, registration gives providers the false impression Edge complies with §503B | Edge: plaintiff fails to plead specific facts showing how the audience was actually misled | Dismissed. Court held plaintiff’s pleading lacked concrete allegations showing how consumers were misled (mere conclusory assertions), so misleadingness claim fails |
| Whether the Superiority Statement ("not ideal for hospital use") is actionable | Azurity: implies competing FDA‑approved drugs (FIRVANQ) are not ideal/are inferior — thus a falsifiable superiority claim | Edge: statement is vague puffery and nonactionable | Dismissed. Court held the statement is vague, subjective puffery (not a specific, measurable superiority claim) |
Key Cases Cited
- POM Wonderful LLC v. Coca‑Cola Co., 573 U.S. 102 (2014) (Supreme Court rejected categorical FDCA preclusion of Lanham Act claims and held parallel enforcement can coexist)
- Clorox Co. P.R. v. Proctor & Gamble Co., 228 F.3d 24 (1st Cir. 2000) (framework for literal falsity vs. misleadingness and examples of puffery vs measurable claims)
- Cashmere & Camel Hair Mfrs. Inst. v. Saks Fifth Ave., 284 F.3d 302 (1st Cir. 2002) (elements of a Lanham Act false advertising claim)
- Coastal Abstract Serv., Inc. v. First Am. Title Ins. Co., 173 F.3d 725 (9th Cir. 1999) (statements that interpret law are not actionable absent a clear agency/court ruling)
- Dial A Car, Inc. v. Transp., Inc., 82 F.3d 484 (D.C. Cir. 1996) (similar rule that legal‑interpretive claims require a clear/unambiguous regulatory statement to be actionable)
- PhotoMedex, Inc. v. Irwin, 601 F.3d 919 (9th Cir. 2010) (pre‑POM decision applying FDCA preclusion principles; discussed as background)
- Amarin Pharma, Inc. v. Int'l Trade Comm'n, 923 F.3d 959 (Fed. Cir. 2019) (FDCA/FDA guidance may limit competitor claims in some contexts but does not broadly preclude all Lanham suits)
- Alpharma, Inc. v. Pennfield Oil Co., 411 F.3d 934 (8th Cir. 2005) (distinguishing questions about whether a product is approved from questions requiring FDA scientific expertise)
- Pejepscot Indus. Park, Inc. v. Me. Cen. R.R. Co., 215 F.3d 195 (1st Cir. 2000) (factors for invoking primary jurisdiction/agency referral)